Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009
Published online before print September 17, 2009, doi: 10.1161/CIRCRESAHA.109.196576
A more recent version of this article appeared on October 23, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
105/9/852    most recent
CIRCRESAHA.109.196576v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lemarié, C. A.
Right arrow Articles by Schiffrin, E. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemarié, C. A.
Right arrow Articles by Schiffrin, E. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Cell signalling/signal transduction
Right arrow Hypertension - basic studies
Right arrow Other Vascular biology

Submitted on February 27, 2009
Revised on September 8, 2009
Accepted on September 9, 2009

Aldosterone-Induced Activation of Signaling Pathways Requires Activity of Angiotensin Type 1a Receptors

Catherine A. Lemarié ; Stefania M.C. Simeone ; Anna Nikonova ; Talin Ebrahimian ; Marie-Eve Deschênes ; Thomas M. Coffman ; Pierre Paradis ; and Ernesto L. Schiffrin *

From the Lady Davis Institute for Medical Research (C.A.L., S.M.C.S., A.N., T.E., M.-E.D., P.P., E.L.S.), Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and Division of Nephrology (T.M.C.), Department of Medicine, Duke University, Durham, NC.

* To whom correspondence should be addressed. E-mail: ernesto.schiffrin{at}mcgill.ca.

Rationale: Aldosterone has been shown to induce vascular damage, endothelial dysfunction, and myocardial fibrosis, which depend in part on activation of angiotensin II (Ang II)–mediated pathways. However, mechanisms underlying crosstalk between Ang II type 1 receptor (AT1R) and mineralocorticoid receptors (MRs) are mostly unknown.

Objectives: We tested whether the lack of Ang II type 1a receptor (AT1aR) or Ang II type 1b receptor (AT1bR) would decrease cellular effects induced by aldosterone.

Methods and Results: We examined the effect of Ang II or aldosterone after transfection of mesenteric vascular smooth muscle cells (VSMCs) from C57Bl/6 mice with small interference RNA for AT1aR, AT1bR, or MRs for 48 hours. Ang II and aldosterone separately induced ERK1/2, c-Jun NH2-terminal protein kinase (JNK), and nuclear factor (NF)-{kappa}B phosphorylation after a 20-minute stimulation. Small interference RNA for AT1aR downregulated phosphorylation of ERK1/2, JNK, and NF-{kappa}B after aldosterone stimulation compared to controls. Downregulation of AT1bR or MRs only abolished the activation of NF-{kappa}B. In VSMCs from C57Bl/6 mice, aldosterone and Ang II induced the activation of the c-fos promoter from 30 minutes to 1 hour. This effect was blocked when using VSMCs from AT1aR knockout mice.

Conclusion: We show for the first time that nongenomic and genomic effects of aldosterone are differentially dependent on activity of both AT1aR and AT1bR. Our data suggest that aldosterone augments AT1R-dependent activation of ERK1/2, JNK, and NF-{kappa}B in VSMCs. We provide mechanistic understanding and experimental in vitro support for the benefit of combination therapy with dual blockade of AT1R and MRs to treat hypertension and progression of heart failure as reported in clinical studies and animal models.


Key words: aldosterone • AT1R • AT1aR • AT1bR • intracellular signaling